Number of bleeding days in first month · women seeking emergency contraception
1 finding from 1 review
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
MII oocytes ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Duration of stimulation (days) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ PCOS (high‐responders) ‐ Own oocytes ‐ Early phase stumulation protocol ‐ Frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Live birth or ongoing pregnancy sensitivity analysis ‐ PCOS (high‐responders) ‐ own oocytes ‐ early phase stimulation protocol ‐ frozen embryo transfer (micronised progesterone 100 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy sensitivity analysis ‐ PCOS… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Length of hospital stay · preterm infants at risk for apnea
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Length of hospital stay · preterm infants with or at risk for apnea of prematurity
The review found no eligible studies for this question.
3 findings from 1 review
Duration of attacks per day (minutes) · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review